COMMENTARY: Review: Antiviral agents reduce risk for influenza in healthy adults and alleviate symptoms faster than placebo

Langley, Joanne M.
September 2006
ACP Journal Club;Sep/Oct2006, Vol. 145 Issue 2, p45
Academic Journal
The article presents comments on studies related to examining whether antiviral agents reduce risk for influenza in healthy adults and alleviate symptoms faster than placebo. For prophylaxis of exposed vulnerable persons or treatment of those at high risk for complications, the most commonly used medications are antiviral. In the case of a poor match between vaccine and the circulating viral strain, antivirals are the only intervention for prophylaxis and treatment.


Related Articles

  • Review: Antiviral agents reduce risk for influenza in healthy adults and alleviate symptoms faster than placebo.  // ACP Journal Club;Sep/Oct2006, Vol. 145 Issue 2, p45 

    The article focuses on a study, which cites that antiviral agents reduce risk of influenza in healthy adults. They also alleviate symptoms faster than placebo. The study also researched whether antiviral agents improve outcomes in affected persons. Randomization method and allocation concealment...

  • Influenza, Influenza Vaccine, and Amantadine/Rimantadine. Zimmerman, Richard Kent; Ruben, Frederick L.; Ahwesh, Ellen R. // Journal of Family Practice;Aug1997, Vol. 45 Issue 2, p107 

    Influenza viruses are highly contagious viruses that are transmitted from person to person, usually by the airborne route. Persons in semi-closed or crowded environments, such as students and residents of nursing homes, are at high risk of exposure. The illness attack rate in children ranges...

  • Dealing with flu in a vaccine-short season. Guthrle, Ellen Whipple // Pharmacy Today;Dec2004, Vol. 10 Issue 12, p5 

    This article focuses on vaccination of influenza. In a normal flu season, 90 million Americans experience symptomatic influenza infections, and 20,00() of them die from related complications. Fortunately, alternatives to the flu vaccine exist. Controlled clinical trials have demonstrated that...

  • Workshop 3: Antivirals and Vaccination for Influenza. Fedson, D.S. // PharmacoEconomics;1999 Supplement 1, Vol. 16 Issue 6, p97 

    Presents a discussion on the aspects related to the antivirals and vaccination in influenza. Usage of the antivirals in unvaccinated individuals; Speculations regarding the replacement of vaccinations by antivirals; Key issues faced during the treatment or vaccination of influenza; Need for an...

  • Vaccines and Antiviral Drugs in Pandemic Preparedness. Monto, Arnold S. // Emerging Infectious Diseases;Jan2006, Vol. 12 Issue 1, p55 

    While measures such as closing schools and social distancing may slow the effects of pandemic influenza, only vaccines and antiviral drugs are clearly efficacious in preventing infection or treating illness. Unless the pandemic strain closely resembles one already recognized, vaccine will not be...

  • A Novel Type of Influenza Vaccine: Safety and Immunogenicity of Replication-Deficient Influenza Virus Created by Deletion of the Interferon Antagonist NS1. Wacheck, Volker; Egorov, Andrej; Groiss, Franz; Pfeiffer, Andrea; Fuereder, Thorsten; Hoeflmayer, Doris; Kundi, Michael; Popow-Kraupp, Therese; Redlberger-Fritz, Monika; Mueller, Christian A.; Cinatl, Jindrich; Michaelis, Martin; Geiler, Janina; Bergmann, Michael; Romanova, Julia; Roethl, Elisabeth; Morokutti, Alexander; Wolschek, Markus; Ferko, Boris; Seipelt, Joachim // Journal of Infectious Diseases;2/1/2010, Vol. 201 Issue 3, p354 

    Background. The nonstructural protein NS1 of influenza virus counteracts the interferon-mediated immune response of the host. By deleting the open reading frame of NS1, we have generated a novel type of influenza vaccine. We studied the safety and immunogenicity of an influenza strain lacking...

  • Asia Needs $100 Million to Fight Bird Flu--United Nations Experts.  // Clinical Infectious Diseases;9/1/2005, Vol. 41 Issue 5, preceding p1 

    This article reports on the assessment made by United Nations experts that Asia needs approximately $100 million in the next 3 years to fight avian flu. Shigeru Omi, the World Health Organization's regional director for Western Pacific, said that the threat of avian influenza is ever present in...

  • The treatment of influenza with antiviral drugs. Stiver, Grant // CMAJ: Canadian Medical Association Journal;1/7/2003, Vol. 168 Issue 1, p49 

    Abstract Influenza vaccination with current inactivated vaccines homologous to the prevalent wild-type virus can reduce influenza illness in 75%-80% of healthy adults. Vaccine is recommended for all individuals with chronic underlying diseases and for those aged 65 years or older. Although...

  • Prevention of Symptomatic Seasonal Influenza in 2005-2006 by Inactivated and Live Attenuated Vaccines. Ohmit, Suzanne E.; Victor, John C.; Teich, Esther R.; Truscon, Rachel K.; Rotthoff, Judy R.; Newton, Duane W.; Campbell, Sarah A.; Boulton, Matthew L.; Monto, Arnold S. // Journal of Infectious Diseases;8/1/2008, Vol. 198 Issue 3, p312 

    Background. The efficacy of influenza vaccines may vary annually. In 2004-2005, when antigenically drifted viruses were circulating, a randomized, placebo-controlled trial involving healthy adults showed that inactivated vaccine appeared to be efficacious, whereas live attenuated vaccine...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics